300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Armenia
Andorra
Colombia
Sudan
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United Kingdom
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Third Swedish National Pension Fund, VC Fund

Third Swedish National Pension Fund

VC Fund

Stockholm, Sweden

Third Swedish National Pension Fund is a VC fund in Stockholm focused on Biotechnology and Manufacturing. Third Swedish National Pension Fund employs different investment strategies in the interest of spreading risk and protecting pensions for current and future pensioners. The firm was founded in 2001 and is headquartered in Stockholm, Sweden.

Total investments:
6
Last investment:
Lead investor:
33%

Last updated:

Industries Third Swedish National Pension Fund invests in

BiotechnologyManufacturingPharmaceuticalAppsRetail

Stages Third Swedish National Pension Fund invests in

Post-IPO EquityVenture - Series UnknownFunding Round

Countries Third Swedish National Pension Fund invests in

SwedenDenmarkIreland

Round sizes

Post-IPO Equity $46M–$85M

Round size

Post-IPO Equity
$46M–$85M

Investment Focus

Industry

  • Biotechnology 3 (50%)
  • Manufacturing 2 (33%)
  • Pharmaceutical 2 (33%)
  • Apps 1 (17%)
  • Retail 1 (17%)
See all 14 industries →

Stage

  • Post-IPO Equity 3 (50%)
  • Venture - Series Unknown 2 (33%)
  • Funding Round 1 (17%)

Country

  • Sweden 4 (67%)
  • Denmark 1 (17%)
  • Ireland 1 (17%)

Investments

CompanyDescriptionRoundLinks
ITAB Shop Concept sells, develops, manufactures and installs complete shop fitting concepts for retail chain stores. The company offers custom-made fitting concepts, innovative solutions for checkout arena and professional lighting systems. $85.1M / Post-IPO Equity / Sep 25, 2024
Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal. $46.2M / Post-IPO Equity / Jun 09, 2023
Northvolt develops sustainable lithium-ion batteries in conjunction with R&D, industrialization, and recycling to support clean energy. It provides electrification and renewable energy storage designed for lithium-ion battery plant to produce batteries for electric vehicles. Northvolt's product is an environment-friendly batterymanufactured with minimal carbon footprint and with recycling technology without compromising with important eco-systems, enabling the auto industry to replace fossil fuels with electricity in an efficient manner. The company aims to establish a supply of sustainable battery cells and systems.In 2016, Paolo Cerruti and Peter Carlsson headquartered the company in Stockholm, Stockholms Lan. $2.8B / Venture - Series Unknown / Jun 09, 2021
Saniona is a research and development company with low burn rate, a world class team and high ambitions. $65M / Post-IPO Equity / Aug 10, 2020
Readly is the new way of reading magazines on tablets and smartphones Readly's mission is simple: To be on the cutting edge of the digital magazine revolution. Our expert management team has more than 25 years of experience in the publishing, digital gaming, and broadcasting industries. Readly has headquarters in Sweden. $16.9M / Venture - Series Unknown / Jun 19, 2019
Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressingits target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises. $11M / Oct 30, 2014

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Poland
Oman
Puerto Rico
Cameroon
Guernsey
Armenia
Andorra
Colombia
Sudan
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
Canada
United Kingdom
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Third Swedish National Pension Fund invest in?

Third Swedish National Pension Fund invests primarily in Biotechnology, Manufacturing and Pharmaceutical startups, most often at Post-IPO Equity and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Third Swedish National Pension Fund's check size?

Third Swedish National Pension Fund typically joins rounds of $46M–$85M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Third Swedish National Pension Fund participates in.

When did Third Swedish National Pension Fund last invest?

The most recent investment recorded for Third Swedish National Pension Fund closed in Sep 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Third Swedish National Pension Fund Third Swedish National Pension Fund Find emails